Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Genomic Instability Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RECQL drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RECQL Recombinant Protein (Helicase Domain / Full Length) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for biochemical ATPase and DNA unwinding assays. |
View RECQL Products |
| Gene Delivery | RECQL Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and target validation. |
View RECQL Products |
| Benchmark Ab | Anti-RECQL Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP validation. |
View RECQL Products |
| Validator | RECQL siRNA Set For target knockdown verification in phenotypic and synthetic lethality assays. |
View RECQL Products |
| Related Target A | WRN (Werner Syndrome RecQ Helicase) Key RecQ family homolog; critical for selectivity profiling in synthetic lethality screens. |
View WRN Products |
| Related Target B | BLM (Bloom Syndrome RecQ Helicase) Homologous helicase involved in DNA replication and repair; essential for off-target counter-screening. |
View BLM Products |
| Related Target C | PARP1 Synergistic pathway target; RECQL inhibition sensitizes BRCA-proficient cells to PARP inhibitors. |
View PARP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| RecQ Family Selectivity (Avoiding WRN/BLM off-target toxicity) | High-purity homologous panel proteins (WRN, BLM, RECQL5) strictly verified by mass spectrometry. |
| High-Throughput ATPase Screening | Enzymatically optimized RECQL recombinant proteins with verified theoretical MW and native fold preservation. |
| Lack of Validated Control Reagents | Sequence-verified clinical benchmark antibodies and high-knockdown efficiency siRNA sets included. |
| Assay Interference & False Positives | Endotoxin-controlled, high-purity (>95%) preparations to eliminate non-specific assay readouts. |
Live RECQL R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RECQL therapeutics is intensifying, with major players shifting focus from traditional chemotherapy sensitizers to targeted synthetic lethal small molecule inhibitors. As first-generation DNA damage response (DDR) therapies reach the clinic, the next wave of R&D is targeting RECQL to overcome PARP inhibitor resistance and exploit specific homologous recombination deficiencies in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Oncology-focused Biotech, Academic Consortia | Breast Cancer, Ovarian Cancer, Glioblastoma | Selectivity Assay (Need Mutant vs WT and RecQ Homolog Panels) |
| RNA Therapeutics / siRNA | Preclinical RNAi Developers | Solid Tumors (Combination therapies) | In vitro knockdown verification (Need high-titer Lentivirus & siRNA) |
| Antibody-Drug Conjugates (ADC) / Novel binders | Early-stage Biotechs | Overexpressing Epithelial Cancers | Epitope mapping & binding affinity (Need high-purity ECD-Fc proteins) |